In the wake of the increase in Current Liabilities in the first quarter 2025, Quick Ratio fell to 9.56 a new company low.

Within Major Pharmaceutical Preparations industry 103 other companies have achieved higher Quick Ratio than Verve Therapeutics Inc in first quarter 2025. While Quick Ratio total ranking in the first quarter 2025 has deteriorated compared to the prior quarter from 256 to 328.

Explain Quick Ratio?
How much Cash & cash equivalents VERV�s has?
What are VERV�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

VERV Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	66.11 %	15.95 %	23.33 %	22.21 %	-6.73 %
Y / Y Cash & cash equivalent Change	-18.02 %	-15.97 %	11.27 %	24.54 %	19.2 %
Quick Ratio MRQ	9.56	12.22	12.66	14.27	19.38
VERV's Total Ranking	# 328	# 256	# 80	# 204	# 123
Seq. Current Liabilities Change	21.14 %	0.63 %	5.64 %	28.99 %	-15.44 %
Seq. Cash & cash equivalent Change	-5.19 %	-2.9 %	-6.26 %	-5.02 %	-2.82 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 104
Healthcare Sector	# 159
Overall Market	# 328

Quick Ratio Statistics
High	Average	Low
48.29	17.77	9.56
(Jun 30 2021)		(Mar 31 2025)

Financial Statements
Verve Therapeutics Inc 's Current Liabilities	$ 52 Millions	Visit VERV's Balance sheet
Verve Therapeutics Inc 's Cash & cash equivalent	$ 497 Millions	Visit VERV's Balance sheet
Source of VERV's Sales		Visit VERV's Sales by Geography

Cumulative Verve Therapeutics Inc 's Quick Ratio

VERV's Quick Ratio for the trailling 12 Months

VERV Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	30.9 %	13.79 %	11.05 %	9.6 %	10.85 %
Y / Y Cash & cash equivalent TTM Growth	-1.87 %	7.99 %	16.66 %	10.34 %	14.17 %
Quick Ratio TTM	12.01	14.29	15.51	16	16.03
Total Ranking TTM	# 2750	# 2928	# 2624	# 2643	# 2160
Seq. Current Liabilities TTM Growth	13.16 %	3.9 %	5.63 %	5.4 %	-1.63 %
Seq. Cash & cash equivalent TTM Growth	-4.86 %	-4.25 %	2.39 %	5.21 %	4.7 %

Quick ratio ranking by company, industry and sector >> Back to VERV Financial Strength Comparisons >> Go to Compare VERV Quick Ratio to its Competitors

On the trailing twelve months basis Due to growth in Current Liabilities in the Q1 2025 to $51.98 millions, cumulative Quick Ratio decreased to 12.01 below the Verve Therapeutics Inc average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 420 other companies have achieved higher Quick Ratio than Verve Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 2750, from total ranking during the twelve months ending fourth quarter 2024 at 2928.

Explain Quick Ratio?
How much Cash & cash equivalents VERV�s has?
What are VERV�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 421
Healthcare Sector	# 840
Within the Market	# 2750

trailing twelve months Quick Ratio Statistics
High	Average	Low
22.68	15.95	12.01
(Mar 31 2022)		(Mar 31 2025)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Immunome Inc	26.18	$ 317.323 Millions	$ 12.119 Millions
Agios Pharmaceuticals Inc	25.40	$ 893.375 Millions	$ 35.170 Millions
Aardvark Therapeutics Inc	25.31	$ 151.260 Millions	$ 5.976 Millions
Anebulo Pharmaceuticals Inc	24.32	$ 13.280 Millions	$ 0.546 Millions
Bicara Therapeutics Inc	24.17	$ 462.065 Millions	$ 19.120 Millions
Mbx Biosciences Inc	22.97	$ 240.786 Millions	$ 10.481 Millions
Structure Therapeutics Inc	22.94	$ 836.882 Millions	$ 36.487 Millions
Tyra Biosciences Inc	22.39	$ 318.943 Millions	$ 14.246 Millions
Avalo Therapeutics Inc	22.28	$ 125.108 Millions	$ 5.615 Millions
Crinetics Pharmaceuticals Inc	22.23	$ 1,274.124 Millions	$ 57.311 Millions
Alto Neuroscience Inc	22.15	$ 160.754 Millions	$ 7.257 Millions
Newamsterdam Pharma Company N v	22.13	$ 808.477 Millions	$ 36.541 Millions
Boundless Bio Inc	21.81	$ 138.253 Millions	$ 6.338 Millions
Contineum Therapeutics Inc	21.31	$ 190.710 Millions	$ 8.949 Millions
Ideaya Biosciences Inc	21.28	$ 1,075.646 Millions	$ 50.538 Millions
Neurogene Inc	20.76	$ 292.602 Millions	$ 14.094 Millions
Edgewise Therapeutics inc	20.67	$ 436.387 Millions	$ 21.115 Millions
Rapt Therapeutics Inc	20.66	$ 179.276 Millions	$ 8.678 Millions
Sagimet Biosciences inc	20.24	$ 144.569 Millions	$ 7.141 Millions
Moonlake Immunotherapeutics	20.02	$ 480.130 Millions	$ 23.981 Millions
Dyne Therapeutics Inc	20.00	$ 677.492 Millions	$ 33.882 Millions
Liquidia Corporation	19.57	$ 169.758 Millions	$ 8.675 Millions
Atea Pharmaceuticals Inc	19.56	$ 425.436 Millions	$ 21.747 Millions
Whitehawk Therapeutics Inc	18.83	$ 231.062 Millions	$ 12.274 Millions
Ventyx Biosciences Inc	18.46	$ 228.807 Millions	$ 12.394 Millions
Keros Therapeutics Inc	18.30	$ 720.541 Millions	$ 39.379 Millions
Stoke Therapeutics Inc	17.56	$ 357.324 Millions	$ 20.350 Millions
Xenon Pharmaceuticals Inc	17.16	$ 549.629 Millions	$ 32.030 Millions
Medicinova Inc	17.14	$ 36.571 Millions	$ 2.134 Millions
Astria Therapeutics Inc	16.93	$ 295.064 Millions	$ 17.426 Millions

Date modified: 2026-09-18T13:11:06+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.